한글목차

세계 OTC 의약품 및 보충제 시장 규모는 2034년까지 CAGR 6.7%로 성장할 것으로 예상됩니다.

처방약 중심의 전통적인 제약 모델은 변화의 시기를 맞이하고 있습니다. 제약사들은 일반의약품과 건강보조식품에 대한 수요 증가에 대응하기 위해 전략적으로 초점을 재조정하고 있습니다. 이러한 변화의 배경에는 소비자 선호도 변화, 자기 관리 의식의 발전, 시장 조사 확대 가능성 등 다양한 요인이 있습니다. 이러한 전환의 주요 영향 중 하나는 소비자가 의약품을 더 쉽게 구할 수 있게 된 것. 일반의약품과 건강보조식품은 처방전 없이도 일반적인 질병에 대처할 수 있는 편리한 수단을 제공함으로써 개인이 자신의 건강을 관리할 수 있는 권한을 부여합니다. 이러한 변화는 자가 관리형 건강관리와 예방적 웰빙을 지향하는 더 광범위한 세계적 추세와 일치합니다. 업계가 계속 진화함에 따라 이러한 변화가 소비자 행동, 시장 역학 및 규제 환경을 어떻게 변화시킬지 주시하는 것이 필수적입니다. 현재 진행 중인 변화는 헬스케어의 중요한 전환점을 의미하며, 개인 건강 관리에서 권한 부여의 중요성을 강조하고 있습니다.

규제 기관은 OTC 의약품과 건강보조식품이 최고 수준의 품질과 효능을 보장하는 데 있어 매우 중요한 역할을 하고 있습니다. 규제 변화는 좋은 결과를 가져다주기도 하지만, 업계 관계자들에게는 도전이 되기도 합니다. 새로운 규정 준수 요건에 대응하기 위해서는 많은 자원이 필요하며, 기업은 제품이 최신 표준을 충족하는지 확인하기 위해 변화하는 상황을 파악해야 합니다. 규제 변화에 대한 지속적인 모니터링과 조정의 필요성은 OTC 시장에서 성공을 유지하기 위한 중요한 측면입니다. 규제 변화의 영향은 국경을 넘어 세계 OTC 시장 역학에 영향을 미칩니다. 여러 지역에서 사업을 운영하는 기업은 다양한 규제 상황에 대처하고 다양한 요구 사항을 준수하기 위해 전략을 조정해야 합니다. 이는 각 지역의 규제를 준수하면서 세계에 존재감을 드러내고자 하는 기업에게는 도전이자 기회이기도 합니다.

세계의 일반의약품 및 건강보조식품(OTC) 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인과 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter의 Five Forces 분석
• PEST 분석

제4장 OTC 의약품 및 보충제 시장 분석 : 카테고리별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 진통제
• 감기/기침/독감 제품
• 위장약
• 안과용 제품
• 여성 케어
• 비타민 및 보충제
• 수면 보조제
• 사마귀 제거제
• 구강 관리 제품
• 식물성 제품
• 금연 제품
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 OTC 의약품 및 보충제 시장 분석 : 형태별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 태블릿
• 캡슐
• 분말
• 연고
• 소프트 캡슐
• 액체
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 OTC 의약품 및 보충제 시장 분석 : 유통 채널별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 약국
• 비타민＆건강식품점
• 온라인 약국
• 식료품점
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제7장 OTC 의약품 및 보충제 시장 분석 : 제품 유형별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 브랜드
• 제네릭
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제8장 OTC 의약품 및 보충제 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제9장 북미의 OTC 의약품 및 보충제 시장 분석

제10장 유럽의 OTC 의약품 및 보충제 시장 분석

제11장 아시아태평양의 OTC 의약품 및 보충제 시장 분석

제12장 라틴아메리카의 OTC 의약품 및 보충제 시장 분석

제13장 중동 및 아프리카의 OTC 의약품 및 보충제 시장 분석

제14장 기업 개요

• 경쟁 구도
• 전략적 전망
• Abbott
• Amway Corporation
• Bayer AG
• Cipla, Inc.
• Dr. Reddy's Laboratories Ltd.
• Glenmark Pharmaceuticals Ltd
• GlaxoSmithKline plc
• Herbalife Nutrition
• Kenvue Inc.
• Nestle SA
• Perrigo Company Inc,
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd

제15장 결론 및 추천 사항

• Visiongain의 결론
• 시장 진출기업을 위한 추천 사항

영문목차

The global OTC Drugs & Dietary Supplements market is projected to grow at a CAGR of 6.7% by 2034.

“The OTC Drugs & Dietary Supplements Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Pharmaceutical companies transitioning from prescription medications to over-the-counter drugs

The traditional model of pharmaceuticals, dominated by prescription medications, is undergoing a transformative phase. Pharmaceutical companies are strategically realigning their focus to cater to the growing demand for OTC drugs and supplements. This transition is driven by various factors, including changing consumer preferences, advancements in self-care awareness, and the potential for expanded market reach. One of the primary impacts of this transition is the increased accessibility of medications for consumers. OTC drugs and supplements empower individuals to take charge of their health, providing a convenient avenue for managing common ailments without the need for a prescription. This shift aligns with a broader global trend towards self-directed healthcare and preventive wellness. As the industry continues to evolve, it is essential to monitor how these changes shape consumer behavior, market dynamics, and regulatory environments. The ongoing transformation signifies a significant milestone in healthcare, emphasizing the importance of empowering individuals in managing their well-being.

Evolving Regulatory Standardizations Will Limit the Growth

One of the key impacts of evolving regulatory bodies is the pursuit of harmonization and standardization. Regulatory agencies globally are working towards aligning standards to ensure consistency in the evaluation and approval processes for OTC drugs and supplements. This move aims to streamline market access, reduce trade barriers, and enhance the overall quality and safety of products available to consumers. Changing regulatory frameworks prioritize consumer safety and confidence by implementing stringent guidelines and monitoring mechanisms. The emphasis on transparency, clear labeling, and comprehensive product information is bolstering consumer trust in OTC products. Regulatory bodies play a pivotal role in ensuring that OTC drugs and supplements meet the highest standards of quality and efficacy. While regulatory changes bring positive outcomes, they also pose challenges for industry players. Adapting to new compliance requirements can be resource-intensive, and companies must navigate the evolving landscape to ensure that their products meet the latest standards. The need for continuous monitoring and adjustment to regulatory changes is a critical aspect of sustaining success in the OTC market. The impact of changing regulatory bodies extends beyond national borders, influencing the global OTC market dynamics. Companies operating in multiple regions must navigate diverse regulatory landscapes, adapting their strategies to comply with varying requirements. This presents both challenges and opportunities as companies strive to create a global presence while adhering to local regulations.

What Questions Should You Ask before Buying a Market Research Report?

• How is the OTC Drugs & Dietary Supplements Market evolving?
• What is driving and restraining the OTC Drugs & Dietary Supplements Market?
• How will each OTC Drugs & Dietary Supplements submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each OTC Drugs & Dietary Supplements submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading OTC Drugs & Dietary Supplements Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the OTC Drugs & Dietary Supplements projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of OTC Drugs & Dietary Supplements projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the OTC Drugs & Dietary Supplements Market?
• Where is the OTC Drugs & Dietary Supplements Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the OTC Drugs & Dietary Supplements Market today, and over the next 10 years:

• Our 337-page report provides 123 tables and 192 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the OTC Drugs & Dietary Supplements Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising OTC Drugs & Dietary Supplements prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

By Categories

• Analgesics
• Cold, cough and Flu Products
• Gastrointestinal Products
• Ophthalmic
• Feminine Care
• Vitamin and Dietary Supplements
• Sleep Aids
• Wart Removers
• Mouth Care Products
• Botanicals
• Smoking Cessation Products

By Dosage Forms

• Tablets
• Capsules
• Powder
• Ointments
• Soft Capsules
• Liquids
• Others

By Distribution Channel

• Pharmacies
• Vitamin & Health Food Store
• Online Pharmacy
• Grocery Stores

By Product Type

• Branded
• Generic

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

Leading companies profiled in the report:

Overall world revenue for OTC Drugs & Dietary Supplements Market, 2024 to 2034 in terms of value the market will surpass US$211.8 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “OTC Drugs & Dietary Supplements Market, 2024 to 2034” report help you?

In summary, our 330+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for OTC Drugs & Dietary Supplements Market, 2024 to 2034 Market, with forecasts for product and end-user, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the OTC Drugs & Dietary Supplements Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 14 of the major companies involved in the OTC Drugs & Dietary Supplements Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the OTC Drugs & Dietary Supplements Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to OTC Drugs & Dietary Supplements
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Pharmaceutical Companies switching from Rx to OTC Drugs
    • 3.2.1.2 Increasing Prevalence of Metabolic Disorders
    • 3.2.1.3 Growing Trend of Self-Medication
    • 3.2.1.4 Increasing Awareness of Nutraceutical Products
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Several concerns pertaining to incorrect diagnosis and substance abuse
    • 3.2.2.2 Challenging regulatory environment
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Increasing Demand for Preventive Healthcare solutions
    • 3.2.3.2 Growing Preference for Natural and Organic Products
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis

4 OTC Drugs & Dietary Supplements Analysis by Categories

• 4.1 Key Findings
• 4.2 Indication Segment: Market Attractiveness Index
• 4.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
• 4.4 Analgesics
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Cold, Cough and Flu Products
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Gastrointestinal Products
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)
• 4.7 Ophthalmic
  • 4.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.7.2 Market Share by Region, 2024 & 2034 (%)
• 4.8 Feminine Care
  • 4.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.8.2 Market Share by Region, 2024 & 2034 (%)
• 4.9 Vitamin and Dietary Supplements
  • 4.9.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.9.2 Market Share by Region, 2024 & 2034 (%)
• 4.10 Sleep Aids
  • 4.10.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.10.2 Market Share by Region, 2024 & 2034 (%)
• 4.11 Wart Removers
  • 4.11.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.11.2 Market Share by Region, 2024 & 2034 (%)
• 4.12 Mouth Care Products
  • 4.12.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.12.2 Market Share by Region, 2024 & 2034 (%)
• 4.13 Botanicals
  • 4.13.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.13.2 Market Share by Region, 2024 & 2034 (%)
• 4.14 Smoking Cessation Products
  • 4.14.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.14.2 Market Share by Region, 2024 & 2034 (%)

5 OTC Drugs & Dietary Supplements Analysis by Dosage Forms

• 5.1 Key Findings
• 5.2 Dosage Forms Segment: Market Attractiveness Index
• 5.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
• 5.4 Tablets
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Capsules
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Powder
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)
• 5.7 Ointments
  • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.7.2 Market Share by Region, 2024 & 2034 (%)
• 5.8 Soft Capsules
  • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.8.2 Market Share by Region, 2024 & 2034 (%)
• 5.9 Liquids
  • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.9.2 Market Share by Region, 2024 & 2034 (%)
• 5.10 Others
  • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.10.2 Market Share by Region, 2024 & 2034 (%)

6 OTC Drugs & Dietary Supplements Analysis by Distribution Channel

• 6.1 Key Findings
• 6.2 Distribution Channel Segment: Market Attractiveness Index
• 6.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
• 6.4 Pharmacies
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
• 6.5 Vitamin & Health Food Store
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)
• 6.6 Online Pharmacy
  • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.6.2 Market Share by Region, 2024 & 2034 (%)
• 6.7 Grocery Stores
  • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.7.2 Market Share by Region, 2024 & 2034 (%)

7 OTC Drugs & Dietary Supplements Analysis by Product Type

• 7.1 Key Findings
• 7.2 Product Type Segment: Market Attractiveness Index
• 7.3 OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
• 7.4 Branded
  • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.4.2 Market Share by Region, 2024 & 2034 (%)
• 7.5 Generic
  • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.5.2 Market Share by Region, 2024 & 2034 (%)

8 OTC Drugs & Dietary Supplements Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America OTC Drugs & Dietary Supplements Analysis

• 9.1 Key Findings
• 9.2 North America OTC Drugs & Dietary Supplements Attractiveness Index
• 9.3 North America OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
• 9.4 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
• 9.5 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
• 9.6 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
• 9.7 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
• 9.8 North America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
• 9.9 U.S. OTC Drugs & Dietary Supplements Analysis
• 9.10 Canada OTC Drugs & Dietary Supplements Analysis

10 Europe OTC Drugs & Dietary Supplements Analysis

• 10.1 Key Findings
• 10.2 Europe OTC Drugs & Dietary Supplements Attractiveness Index
• 10.3 Europe OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
• 10.5 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
• 10.6 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
• 10.7 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
• 10.8 Europe OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
• 10.9 Germany OTC Drugs & Dietary Supplements Analysis
• 10.10 France OTC Drugs & Dietary Supplements Analysis
• 10.11 UK OTC Drugs & Dietary Supplements Analysis
• 10.12 Italy OTC Drugs & Dietary Supplements Analysis
• 10.13 Spain OTC Drugs & Dietary Supplements Analysis
• 10.14 Russia OTC Drugs & Dietary Supplements Analysis
• 10.15 Rest of Europe OTC Drugs & Dietary Supplements Analysis

11 Asia Pacific OTC Drugs & Dietary Supplements Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific OTC Drugs & Dietary Supplements Attractiveness Index
• 11.3 Asia Pacific OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
• 11.4 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
• 11.5 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
• 11.6 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
• 11.7 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
• 11.8 Asia Pacific OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
• 11.9 Japan OTC Drugs & Dietary Supplements Analysis
• 11.10 China OTC Drugs & Dietary Supplements Analysis
• 11.11 India OTC Drugs & Dietary Supplements Analysis
• 11.12 Australia OTC Drugs & Dietary Supplements Analysis
• 11.13 South Korea OTC Drugs & Dietary Supplements Analysis
• 11.14 Rest of Asia Pacific OTC Drugs & Dietary Supplements Analysis

12 Latin America OTC Drugs & Dietary Supplements Analysis

• 12.1 Key Findings
• 12.2 Latin America OTC Drugs & Dietary Supplements Attractiveness Index
• 12.3 Latin America OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
• 12.4 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
• 12.5 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
• 12.6 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
• 12.7 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
• 12.8 Latin America OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
• 12.9 Brazil OTC Drugs & Dietary Supplements Analysis
• 12.10 Mexico OTC Drugs & Dietary Supplements Analysis
• 12.11 Rest of Latin America OTC Drugs & Dietary Supplements Analysis

13 MEA OTC Drugs & Dietary Supplements Analysis

• 13.1 Key Findings
• 13.2 MEA OTC Drugs & Dietary Supplements Attractiveness Index
• 13.3 MEA OTC Drugs & Dietary Supplements by Country, 2024, 2029 & 2034 (US$ Billion)
• 13.4 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Country
• 13.5 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Categories
• 13.6 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Dosage Forms
• 13.7 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Distribution Channel
• 13.8 MEA OTC Drugs & Dietary Supplements Size Estimation and Forecast by Product Type
• 13.9 GCC OTC Drugs & Dietary Supplements Analysis
• 13.10 South Africa OTC Drugs & Dietary Supplements Analysis
• 13.11 Rest of MEA OTC Drugs & Dietary Supplements Analysis

14 Company Profiles

• 14.1 Competitive Landscape, 2023
• 14.2 Strategic Outlook
• 14.3 Abbott
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2017-2022
    • 14.3.3.2 R&D, 2017-2022
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 Amway Corporation
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Net Revenue, 2017-2022
  • 14.4.4 Product Benchmarking
  • 14.4.5 Strategic Outlook
• 14.5 Bayer AG
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Net Revenue, 2017-2022
    • 14.5.3.2 R&D, 2017-2022
    • 14.5.3.3 Regional Market Shares, 2022
  • 14.5.4 Product Benchmarking
  • 14.5.5 Strategic Outlook
• 14.6 Cipla, Inc.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Net Revenue, 2017-2022
    • 14.6.3.2 Regional Market Shares, 2022
  • 14.6.4 Product Benchmarking
  • 14.6.5 Strategic Outlook
• 14.7 Dr. Reddy's Laboratories Ltd.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Net Revenue, 2017-2022
    • 14.7.3.2 R&D, 2017-2022
    • 14.7.3.3 Regional Market Shares, 2022
  • 14.7.4 Product Benchmarking
  • 14.7.5 Strategic Outlook
• 14.8 Glenmark Pharmaceuticals Ltd
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Financial Analysis
    • 14.8.3.1 Net Revenue, 2017-2022
    • 14.8.3.2 Regional Market Shares, 2022
  • 14.8.4 Product Benchmarking
  • 14.8.5 Strategic Outlook
• 14.9 GlaxoSmithKline plc
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Net Revenue, 2017-2022
    • 14.9.3.2 R&D, 2017-2022
    • 14.9.3.3 Regional Market Shares, 2022
  • 14.9.4 Product Benchmarking
  • 14.9.5 Strategic Outlook
• 14.10 Herbalife Nutrition
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
    • 14.10.3.1 Net Revenue, 2017-2022
    • 14.10.3.2 Regional Market Shares, 2022
  • 14.10.4 Product Benchmarking
  • 14.10.5 Strategic Outlook
• 14.11 Kenvue Inc. (Previously J & J Services Business Division)
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Net Revenue, 2017-2022
    • 14.11.3.2 R&D, 2017-2022
    • 14.11.3.3 Regional Market Shares, 2022
  • 14.11.4 Product Benchmarking
  • 14.11.5 Strategic Outlook
• 14.12 Nestle SA
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Financial Analysis
    • 14.12.3.1 Net Revenue, 2017-2022
    • 14.12.3.2 R&D, 2017-2022
    • 14.12.3.3 Regional Market Shares, 2022
  • 14.12.4 Product Benchmarking
  • 14.12.5 Strategic Outlook
• 14.13 Perrigo Company Inc,
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Net Revenue, 2017-2022
    • 14.13.3.2 R&D, 2017-2022
    • 14.13.3.3 Regional Market Shares, 2022
  • 14.13.4 Product Benchmarking
  • 14.13.5 Strategic Outlook
• 14.14 Pfizer Inc.
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Financial Analysis
    • 14.14.3.1 Net Revenue, 2017-2022
    • 14.14.3.2 R&D, 2017-2022
    • 14.14.3.3 Regional Market Shares, 2022
  • 14.14.4 Product Benchmarking
  • 14.14.5 Strategic Outlook
• 14.15 Sanofi
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Financial Analysis
    • 14.15.3.1 Net Revenue, 2017-2022
    • 14.15.3.2 R&D, 2017-2022
  • 14.15.4 Product Benchmarking
  • 14.15.5 Strategic Outlook
• 14.16 Sun Pharmaceutical Industries Ltd
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Financial Analysis
    • 14.16.3.1 Net Revenue, 2017-2022
    • 14.16.3.2 Regional Market Shares, 2022
  • 14.16.4 Product Benchmarking
  • 14.16.5 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players